Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. announced
today the appointment of Patrice R. Debregeas to its board of
directors. As Chairman, CEO and President of Ethypharm S.A, the
leading drug delivery company in Europe, Mr. Debregeas brings
extensive international experience in the pharmaceutical sector.
Under the supervision of Mr. Debregeas, Ethypharm has successfully
launched 50 products in over 70 countries.
Mr. Debregeas holds an MBA from Wharton Graduate School of
Business at the University of Pennsylvania and an M.S. in Pharmacy
from the University of Paris. "I am most excited to be joining the
Board of Directors for Isotechnika Inc., a Company that is
developing a very strong pipeline of therapeutic products and a new
test for insulin resistance that could change the diagnosis of
diabetic patients worldwide," stated Mr. Debregeas.
"It is both a pleasure and a privilege to welcome Patrice
Debregeas to our board of directors," stated Dr. Robert Foster,
Isotechnika's Chairman and CEO. "Mr. Debregeas' years of experience
in the delivery of pharmaceutical products will be a valuable asset
as our lead drug candidate , ISA247 advances towards a Phase III
psoriasis trial later this year."
About Isotechnika Inc.
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world- class team of scientists are
building a pipeline of immunosuppressive drug candidates for use in
the prevention of organ rejection in transplantation and in the
treatment of autoimmune diseases. Isotechnika looks to become the
leader in development of immunosuppressant therapies.
Isotechnika's lead drug, ISA247, presently referred to as
trans-ISA247, is an immunosuppressant that has successfully
completed a Phase II trial for psoriasis and Phase IIa trial for
kidney transplantation. Isotechnika recently expanded its product
pipeline by developing two additional novel immunosuppressive
compounds, TAFA93 and TKB662. TAFA93 is a novel small molecule mTOR
inhibitor, a class of drugs currently used in the prevention of
organ rejection in transplantation and as a coated stent therapy in
the treatment of coronary artery disease. Pre-clinical studies of
TKB662 have demonstrated inhibition of T cell and B cell activation
and proliferation through multiple mechanisms of action including
the inhibition of lymphocyte phosphorylation activity. As both
TAFA93 and TKB662 have distinct mechanisms of action from
calcineurin inhibitors such as ISA247 they have the potential to be
administered as complementary therapies in both prevention of organ
rejection and treatment of autoimmune diseases.
In addition to the Company's drug pipeline, Isotechnika also has a
diagnostic division, which includes the Helikit(TM) and Diatest(TM)
breath kits. The Helikit(TM), a (13)C breath test is used for the
detection of H. pylori, a bacterium that infects a large portion of
the population. The Helikit(TM) is currently sold internationally.
The Diatest(TM), a (13)C glucose breath test is used for the
detection of insulin resistance. The Company expects to commence the
necessary clinical trials in 2005 involving the Diatest(TM) to
obtain regulatory approval in the United States.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.
This press release may contain forward-looking statements.
Forward-looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the availability
of funds and resources to pursue research and development projects,
the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical
studies and trials, the Company's ability to successfully
commercialize its products, the ability of the Company to defend its
patents from infringement by third parties, and the risk that the
Company's patents may be subsequently shown to be invalid or infringe
the patents of others. Investors should consult the Company's
quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements.
Archived images on this organization are available through CNW
E-Pix at http://www.newswire.ca. Images are free to members of The
Canadian Press. To request a free copy of this organization's annual
report, please go to http://www.newswire.ca and click on reports@cnw.
ots Originaltext: Isotechnika Inc.
Im Internet recherchierbar: http://www.newsaktuell.ch
For further information: Dr. Robert Foster, Chairman & CEO,
Isotechnika Inc., +1(780)-487-1600 ext. 246, +1(780)-484-4105 (fax),
email@example.com; Stephanie Gillis-Paulgaard, Manager,
Corporate Communications, Isotechnika Inc., +1(780)-487-1600 ext.
243, +1(780)-484-4105 (fax), firstname.lastname@example.org